Research graph
References from Predicting Neoantigen Immunogenicity from <i>In Vivo</i> Immune Editing. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41586-023-06063-y
10.1038/s41586-023-06063-y · External reference
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
10.1038/s41591-025-03627-5 · 2025 · External reference
10.1056/nejmoa2119662
10.1056/nejmoa2119662 · External reference
10.1126/scitranslmed.aax7918
10.1126/scitranslmed.aax7918 · External reference
10.1038/s41586-022-04735-9
10.1038/s41586-022-04735-9 · External reference
10.3389/fonc.2019.01161
10.3389/fonc.2019.01161 · External reference
10.1038/s41587-024-02420-y
10.1038/s41587-024-02420-y · External reference
10.1016/j.ccell.2022.10.013
10.1016/j.ccell.2022.10.013 · External reference
10.1038/s41392-022-01270-x
10.1038/s41392-022-01270-x · External reference
10.1158/2159-8290.cd-18-1494
10.1158/2159-8290.cd-18-1494 · External reference
10.1016/j.cell.2020.09.015
10.1016/j.cell.2020.09.015 · External reference
10.1038/nature22991
10.1038/nature22991 · External reference
10.1016/j.cell.2025.06.019
10.1016/j.cell.2025.06.019 · External reference
10.1038/s41586-024-08507-5
10.1038/s41586-024-08507-5 · External reference
10.1172/jci134915
10.1172/jci134915 · External reference
10.1038/s41591-021-01462-y
10.1038/s41591-021-01462-y · External reference
10.3389/fimmu.2025.1616113
10.3389/fimmu.2025.1616113 · External reference
10.1126/sciadv.adj6367
10.1126/sciadv.adj6367 · External reference
10.1056/nejmoa1012863
10.1056/nejmoa1012863 · External reference
10.1016/j.xcrm.2021.100194
10.1016/j.xcrm.2021.100194 · External reference
Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity,” Nat
10.1038/s42256-023-00694-6 · 2023 · External reference
10.1093/bib/bbad116
10.1093/bib/bbad116 · External reference
10.3389/fimmu.2018.01369
10.3389/fimmu.2018.01369 · External reference
10.1038/s41586-024-08508-4
10.1038/s41586-024-08508-4 · External reference
10.1038/s41467-026-68651-6
10.1038/s41467-026-68651-6 · External reference
Persistent mutation burden drives sustained anti-tumor immune responses
10.1038/s41591-022-02163-w · 2023 · External reference
10.1093/bioinformatics/btaf344
10.1093/bioinformatics/btaf344 · External reference
10.1038/s41588-020-0687-1
10.1038/s41588-020-0687-1 · External reference
Personalized neoantigen cancer vaccines: An analysis of the clinical and commercial potential of ongoing development programs
10.1016/j.drudis.2023.103773 · 2023 · External reference
10.1016/j.cell.2017.10.001
10.1016/j.cell.2017.10.001 · External reference
10.1038/s41588-023-01313-1
10.1038/s41588-023-01313-1 · External reference
10.1038/s41588-024-01883-8
10.1038/s41588-024-01883-8 · External reference
10.1200/jco-26-00769
10.1200/jco-26-00769 · External reference
10.1016/j.ccell.2022.10.013
10.1016/j.ccell.2022.10.013 · ExternalCitation · doi-reference
10.1016/j.cell.2017.10.001
10.1016/j.cell.2017.10.001 · ExternalCitation · doi-reference
10.1016/j.cell.2020.09.015
10.1016/j.cell.2020.09.015 · ExternalCitation · doi-reference
10.1016/j.cell.2025.06.019
10.1016/j.cell.2025.06.019 · ExternalCitation · doi-reference
Personalized neoantigen cancer vaccines: An analysis of the clinical and commercial potential of ongoing development programs
10.1016/j.drudis.2023.103773 · ExternalCitation · doi-reference
10.1016/j.xcrm.2021.100194
10.1016/j.xcrm.2021.100194 · ExternalCitation · doi-reference
10.1038/nature22991
10.1038/nature22991 · ExternalCitation · doi-reference
10.1038/s41392-022-01270-x
10.1038/s41392-022-01270-x · ExternalCitation · doi-reference
10.1038/s41467-026-68651-6
10.1038/s41467-026-68651-6 · ExternalCitation · doi-reference
10.1038/s41586-022-04735-9
10.1038/s41586-022-04735-9 · ExternalCitation · doi-reference
10.1038/s41586-023-06063-y
10.1038/s41586-023-06063-y · ExternalCitation · doi-reference
10.1038/s41586-024-08507-5
10.1038/s41586-024-08507-5 · ExternalCitation · doi-reference
10.1038/s41586-024-08508-4
10.1038/s41586-024-08508-4 · ExternalCitation · doi-reference
10.1038/s41587-024-02420-y
10.1038/s41587-024-02420-y · ExternalCitation · doi-reference
10.1038/s41588-020-0687-1
10.1038/s41588-020-0687-1 · ExternalCitation · doi-reference
10.1038/s41588-023-01313-1
10.1038/s41588-023-01313-1 · ExternalCitation · doi-reference
10.1038/s41588-024-01883-8
10.1038/s41588-024-01883-8 · ExternalCitation · doi-reference
10.1038/s41591-021-01462-y
10.1038/s41591-021-01462-y · ExternalCitation · doi-reference
Persistent mutation burden drives sustained anti-tumor immune responses
10.1038/s41591-022-02163-w · ExternalCitation · doi-reference
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
10.1038/s41591-025-03627-5 · ExternalCitation · doi-reference
Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity,” Nat
10.1038/s42256-023-00694-6 · ExternalCitation · doi-reference
10.1056/nejmoa1012863
10.1056/nejmoa1012863 · ExternalCitation · doi-reference
10.1056/nejmoa2119662
10.1056/nejmoa2119662 · ExternalCitation · doi-reference
10.1093/bib/bbad116
10.1093/bib/bbad116 · ExternalCitation · doi-reference
10.1093/bioinformatics/btaf344
10.1093/bioinformatics/btaf344 · ExternalCitation · doi-reference
10.1126/sciadv.adj6367
10.1126/sciadv.adj6367 · ExternalCitation · doi-reference
10.1126/scitranslmed.aax7918
10.1126/scitranslmed.aax7918 · ExternalCitation · doi-reference
10.1158/2159-8290.cd-18-1494
10.1158/2159-8290.cd-18-1494 · ExternalCitation · doi-reference
10.1172/jci134915
10.1172/jci134915 · ExternalCitation · doi-reference
10.1200/jco-26-00769
10.1200/jco-26-00769 · ExternalCitation · doi-reference
10.3389/fimmu.2018.01369
10.3389/fimmu.2018.01369 · ExternalCitation · doi-reference
10.3389/fimmu.2025.1616113
10.3389/fimmu.2025.1616113 · ExternalCitation · doi-reference
10.3389/fonc.2019.01161
10.3389/fonc.2019.01161 · ExternalCitation · doi-reference
